Richard Kim, M.D.
H. Lee Moffitt Cancer Center and Research Institute
11
10
10
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+11 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Renuka Iyer, M.D.
Roswell Park Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Saleh K Saleh, MD
Minia University
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch
Shared therapeutic areas:
Worked with same sponsors:
Gao-Jun Teng, MD
Zhongda Hospital
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Phase I Trial of Combination of FOLFIRI and SOM 230
All 11 trials loaded